Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.

中文翻译：

---

前列腺癌的无进展生存终点：我们是否真正取得了进展


最近，前列腺癌的几种治疗策略仅基于无进展生存获益就获得了监管部门的批准，这是前列腺癌治疗发展的相对变化。此前，总生存期是批准的一个要求。这种方法是否合理或对患者有益仍不清楚。